

Paul Savage

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8560906/publications.pdf>

Version: 2024-02-01

11
papers

430
citations

1170033

9
h-index

1526636

10
g-index

11
all docs

11
docs citations

11
times ranked

1014
citing authors

#	ARTICLE	IF	CITATIONS
1	p66ShcA potentiates the cytotoxic response of triple negative breast cancers to PARP inhibitors. JCI Insight, 2021, 6, .	2.3	0
2	Co-dependency for MET and FGFR1 in basal triple-negative breast cancers. Npj Breast Cancer, 2021, 7, 36.	2.3	12
3	STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. Nature Communications, 2021, 12, 3299.	5.8	24
4	Invasive growth associated with cold-inducible RNA-binding protein expression drives recurrence of surgically resected brain metastases. Neuro-Oncology, 2021, 23, 1470-1480.	0.6	18
5	Epigenetic Switchâ€“Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer. Cancer Discovery, 2020, 10, 1312-1329.	7.7	84
6	Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors. Communications Biology, 2020, 3, 310.	2.0	28
7	An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. Nature Communications, 2019, 10, 2901.	5.8	24
8	The effect of the American Joint Committee on Cancer eighth edition on breast cancer staging and prognostication. European Journal of Surgical Oncology, 2019, 45, 1817-1820.	0.5	9
9	Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. Nature Communications, 2018, 9, 2547.	5.8	63
10	A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer. Cell Reports, 2017, 21, 1140-1149.	2.9	70
11	ERRÎ± mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nature Communications, 2016, 7, 12156.	5.8	98